119th Congress · introduced in the Senate · Feb 11, 2025
Prescription Pricing for the People Act of 2025
Official title from Congress.gov
Latest action (Apr 10, 2025): Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
View on Congress.govPolicy area: Commerce
Congressional Research Service summary, version: Introduced in Senate (Feb 11, 2025)
Prescription Pricing for the People Act of 2025
This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.
The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.
The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.
Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Actions from Congress.gov, newest first.
Business ethics · Business records · Competition and antitrust · Congressional oversight · Consumer affairs · Health care costs and insurance · Health information and medical records · Inflation and prices · Prescription drugs · Retail and wholesale trades · Supply chain
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
95 citations; showing the 25 most recently posted.
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION · lobbying firm or registrant: NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Labor Issues/Antitrust/Workplace
$370,000
Spent on own lobbying
S.526, the Pharmacy Benefit Manager Transparency Act of 2025; S.527, the Prescription Pricing for the People Act of 2025; Comments to Department of Labor RE: "Re: Reforming Pharmacy Benefit Manager (PBM) Compensation Practices"…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Copyright/Patent/Trademark
$2,560,000
Spent on own lobbying
…ating Thickets to Increase Competition (ETHIC) Act ---H.R.9142: Prohibiting Adversarial Patents Act of 2026 ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Afford…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$2,560,000
Spent on own lobbying
…nd Traceability Drug Patenting ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Afford…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$2,560,000
Spent on own lobbying
…cturing ---Compounded Medicines ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interage…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
FAMILIES USA FOUNDATION INC · lobbying firm or registrant: FAMILIES USA FOUNDATION, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$30,000
Spent on own lobbying
S.527Prescription Pricing for the People Act of 2025To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain an…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHAIN DRUG STORES · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHAIN DRUG STORES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$480,000
Spent on own lobbying
…Retail Crime Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 526 Pharmacy Benefit Manager (PBM) Transparency Act S. 527 Prescription Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 1404 Combating Organized Ret…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN COLLEGE OF RHEUMATOLOGY · lobbying firm or registrant: AMERICAN COLLEGE OF RHEUMATOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$50,000
Spent on own lobbying
…p Ensure Lower Patient (HELP) Copays Act (S. 864) Patients Before Middlemen Act (S. 882) PBM Transparency Act (S. 526) Prescription Pricing for the People Act (S. 527) Conrad State 30 and Physician Access Reauthorization Act (HR 1585 / S 709) Resident Physician Shortage Reduction Act (HR.3890/S. 2439) Improving Seniors Timel…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN COLLEGE OF RHEUMATOLOGY · lobbying firm or registrant: AMERICAN COLLEGE OF RHEUMATOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Budget/Appropriations
$50,000
Spent on own lobbying
…p Ensure Lower Patient (HELP) Copays Act (S. 864) Patients Before Middlemen Act (S. 882) PBM Transparency Act (S. 526) Prescription Pricing for the People Act (S. 527) Conrad State 30 and Physician Access Reauthorization Act (HR 1585 / S 709) Resident Physician Shortage Reduction Act (HR.3890/S. 2439) Improving Seniors Timel…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN COLLEGE OF RHEUMATOLOGY · lobbying firm or registrant: AMERICAN COLLEGE OF RHEUMATOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$50,000
Spent on own lobbying
…p Ensure Lower Patient (HELP) Copays Act (S. 864) Patients Before Middlemen Act (S. 882) PBM Transparency Act (S. 526) Prescription Pricing for the People Act (S. 527) Conrad State 30 and Physician Access Reauthorization Act (HR 1585 / S 709) Resident Physician Shortage Reduction Act (HR.3890/S. 2439) Improving Seniors Timel…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COUNCIL FOR INNOVATION PROMOTION (C4IP) · lobbying firm or registrant: COUNCIL FOR INNOVATION PROMOTION (C4IP)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Copyright/Patent/Trademark
$90,000
Spent on own lobbying
…RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN MEDICAL ASSOCIATION · lobbying firm or registrant: AMERICAN MEDICAL ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Pharmacy
$4,540,000
Spent on own lobbying
…ring Timely Access to Generics Act S.3822 - Break Up Big Medicine Act, all provisions S.526 - Pharmacy Benefit Manager Transparency Act of 2025, all provisions S.527 - Prescription Pricing for the People Act of 2025, all provisions Matters related to Drug Shortages Matters related to Competition and Transparency of Prescrip…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: CROSSROADS STRATEGIES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 17, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
…027 National Defense Authorization Act, H.R.8800/S.4784); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interage…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VIATRIS (MYLAN, INC) · lobbying firm or registrant: S-3 GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Copyright/Patent/Trademark
$60,000
Paid to lobbying firm
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INDEPENDENT PHARMACY COOPERATIVE · lobbying firm or registrant: INDEPENDENT PHARMACY COOPERATIVE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 8, 2026 · issue area: Pharmacy
$30,000
Spent on own lobbying
IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - "Main Street Pharmacy Access…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
FAMILIES USA FOUNDATION INC · lobbying firm or registrant: FAMILIES USA FOUNDATION, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 30, 2026 · issue area: Pharmacy
$9,000
Spent on own lobbying
S.527Prescription Pricing for the People Act of 2025To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain an…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Copyright/Patent/Trademark
$2,360,000
Spent on own lobbying
…ating Thickets to Increase Competition (ETHIC) Act ---H.R.9142: Prohibiting Adversarial Patents Act of 2026 ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Afford…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Health Issues
$2,360,000
Spent on own lobbying
…nd Traceability Drug Patenting ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.6485/S.43: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Afford…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Medicare/Medicaid
$2,360,000
Spent on own lobbying
…cturing ---Compounded Medicines ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interage…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN COLLEGE OF RHEUMATOLOGY · lobbying firm or registrant: AMERICAN COLLEGE OF RHEUMATOLOGY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$180,000
Spent on own lobbying
…p Ensure Lower Patient (HELP) Copays Act (S. 864) Patients Before Middlemen Act (S. 882) PBM Transparency Act (S. 526) Prescription Pricing for the People Act (S. 527) Conrad State 30 and Physician Access Reauthorization Act (HR 1585 / S 709) Resident Physician Shortage Reduction Act (HR.3890/S. 2439) Improving Seniors Timel…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN COLLEGE OF RHEUMATOLOGY · lobbying firm or registrant: AMERICAN COLLEGE OF RHEUMATOLOGY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Budget/Appropriations
$180,000
Spent on own lobbying
…p Ensure Lower Patient (HELP) Copays Act (S. 864) Patients Before Middlemen Act (S. 882) PBM Transparency Act (S. 526) Prescription Pricing for the People Act (S. 527) Conrad State 30 and Physician Access Reauthorization Act (HR 1585 / S 709) Resident Physician Shortage Reduction Act (HR.3890/S. 2439) Improving Seniors Timel…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN COLLEGE OF RHEUMATOLOGY · lobbying firm or registrant: AMERICAN COLLEGE OF RHEUMATOLOGY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$180,000
Spent on own lobbying
…p Ensure Lower Patient (HELP) Copays Act (S. 864) Patients Before Middlemen Act (S. 882) PBM Transparency Act (S. 526) Prescription Pricing for the People Act (S. 527) Conrad State 30 and Physician Access Reauthorization Act (HR 1585 / S 709) Resident Physician Shortage Reduction Act (HR.3890/S. 2439) Improving Seniors Timel…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHAIN DRUG STORES · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHAIN DRUG STORES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Pharmacy
$290,000
Spent on own lobbying
…Retail Crime Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 526 Pharmacy Benefit Manager (PBM) Transparency Act S. 527 Prescription Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 1404 Combating Organized Ret…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN MEDICAL ASSOCIATION · lobbying firm or registrant: AMERICAN MEDICAL ASSOCIATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · amended · posted Jul 20, 2026 · issue area: Pharmacy
$5,130,000
Spent on own lobbying
S.3822 - Break Up Big Medicine Act, all provisions S.526 - Pharmacy Benefit Manager Transparency Act of 2025, all provisions S.527 - Prescription Pricing for the People Act of 2025, all provisions Draft: Removal of oral phenylephrine from the Food and Drug Administrations over-the-counter…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COUNCIL FOR INNOVATION PROMOTION (C4IP) · lobbying firm or registrant: COUNCIL FOR INNOVATION PROMOTION (C4IP)
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Copyright/Patent/Trademark
$90,000
Spent on own lobbying
…RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: CROSSROADS STRATEGIES, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 18, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
…027 National Defense Authorization Act, H.R.8800/S.4784); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interage…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing